-
1
-
-
0033863012
-
Role of galectin-3 as a receptor for advanced glycosylation end products
-
Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, Cordone S, et al. Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int Suppl 2000; 77: s31-s39.
-
(2000)
Kidney Int Suppl
, vol.77
-
-
Pricci, F.1
Leto, G.2
Amadio, L.3
Iacobini, C.4
Romeo, G.5
Cordone, S.6
-
2
-
-
0034813639
-
The role of galectin-3 in endocytosis of advanced glycosylation end products and modified low density lipoproteins
-
Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycosylation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001; 280: 1183-1188.
-
(2001)
Biochem Biophys Res Commun
, vol.280
, pp. 1183-1188
-
-
Zhu, W.1
Sano, H.2
Nagai, R.3
Fukuhara, K.4
Miyazaki, A.5
Horiuchi, S.6
-
3
-
-
17944369113
-
Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice
-
Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 2001; 15: 2471-2479.
-
(2001)
FASEB J
, vol.15
, pp. 2471-2479
-
-
Pugliese, G.1
Pricci, F.2
Iacobini, C.3
Leto, G.4
Amadio, L.5
Barsotti, P.6
-
4
-
-
13644263258
-
Oral antidiabetic agents
-
Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs 2005; 65: 385-411.
-
(2005)
Drugs
, vol.65
, pp. 385-411
-
-
Krentz, A.J.1
Bailey, C.J.2
-
5
-
-
19244365650
-
Thiazolidinediones
-
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Järvinen, H.1
-
6
-
-
23644456172
-
Therapeutic roles of peroxisome proliferator-activated receptor agonists
-
Staels B, Fruchart J. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54: 2460-2470.
-
(2005)
Diabetes
, vol.54
, pp. 2460-2470
-
-
Staels, B.1
Fruchart, J.2
-
7
-
-
0037258604
-
Rosiglitazone reduces urinary albumin excretion in type II diabetes
-
Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
-
(2003)
J Hum Hypertens
, vol.17
, pp. 7-12
-
-
Bakris, G.1
Viberti, G.2
Weston, W.M.3
Heise, M.4
Porter, L.E.5
Freed, M.I.6
-
8
-
-
30544448497
-
Reduction of serum advanced glycosylation end products-peptide and monocyte chemoattractant protein-1 by rosiglitazone in type 2 diabetic rats
-
Sun ZL, Liu NF, Sun YZ, Wei Q, Zhang Y, Sun GJ, et al. Reduction of serum advanced glycosylation end products-peptide and monocyte chemoattractant protein-1 by rosiglitazone in type 2 diabetic rats. J Chin Pharm Univ (Chin) 2005; 36: 559-562.
-
(2005)
J Chin Pharm Univ (Chin)
, vol.36
, pp. 559-562
-
-
Sun, Z.L.1
Liu, N.F.2
Sun, Y.Z.3
Wei, Q.4
Zhang, Y.5
Sun, G.J.6
-
9
-
-
34248664111
-
Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells
-
Yan HD, Li XZ, Xie JM, Li M. Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells. Chin Med J 2007; 120: 787-793.
-
(2007)
Chin Med J
, vol.120
, pp. 787-793
-
-
Yan, H.D.1
Li, X.Z.2
Xie, J.M.3
Li, M.4
-
10
-
-
68149155918
-
Expression of advanced glycation end products receptors on human joint synovial cells
-
Hou FF, Jiang JP, Zhang X. Expression of advanced glycation end products receptors on human joint synovial cells. Chin J Nephrol (Chin) 2000; 16: 163-168.
-
(2000)
Chin J Nephrol (Chin)
, vol.16
, pp. 163-168
-
-
Hou, F.F.1
Jiang, J.P.2
Zhang, X.3
-
11
-
-
17644434954
-
The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression
-
Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, et al. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 2000; 49: 1249-1257.
-
(2000)
Diabetes
, vol.49
, pp. 1249-1257
-
-
Pugliese, G.1
Pricci, F.2
Leto, G.3
Amadio, L.4
Iacobini, C.5
Romeo, G.6
-
12
-
-
0346368386
-
Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells
-
Seki N, Hashimoto N, Sano H, Horiuchi S, Yagui K, Makino H, et al. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism 2003; 52: 1558-1563.
-
(2003)
Metabolism
, vol.52
, pp. 1558-1563
-
-
Seki, N.1
Hashimoto, N.2
Sano, H.3
Horiuchi, S.4
Yagui, K.5
Makino, H.6
-
13
-
-
10744225343
-
Galectin-3-positive cell infiltration in human diabetic nephropathy
-
Kikuchi Y, Kobayashi S, Hemmi N, Ikee R, Hyodo N, Saigusa T, et al. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 602-607.
-
(2004)
Nephrol Dial Transplant
, vol.19
, pp. 602-607
-
-
Kikuchi, Y.1
Kobayashi, S.2
Hemmi, N.3
Ikee, R.4
Hyodo, N.5
Saigusa, T.6
-
14
-
-
11144267118
-
Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium
-
McFarlane S, Glenn JV, Lichanska AM, Simpson DA, Stitt AW. Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. Br J Ophthalmol 2005; 89: 107-112.
-
(2005)
Br J Ophthalmol
, vol.89
, pp. 107-112
-
-
McFarlane, S.1
Glenn, J.V.2
Lichanska, A.M.3
Simpson, D.A.4
Stitt, A.W.5
-
15
-
-
18144439603
-
Role of galectin-3 in diabetic nephropathy
-
Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 2003; 14 (8 Suppl 3): s264-s270.
-
(2003)
J Am Soc Nephrol
, vol.14
, Issue.8 SUPPL. 3
-
-
Iacobini, C.1
Amadio, L.2
Oddi, G.3
Ricci, C.4
Barsotti, P.5
Missori, S.6
-
16
-
-
9444289275
-
Galectin-3/AGE-receptor 3 knock out mice show accelerated AGE-induced glomerular injury: Evidence for a protective role of galectin-3 as an AGE receptor
-
Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, et al. Galectin-3/AGE-receptor 3 knock out mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004; 18: 1773-1775.
-
(2004)
FASEB J
, vol.18
, pp. 1773-1775
-
-
Iacobini, C.1
Menini, S.2
Oddi, G.3
Ricci, C.4
Amadio, L.5
Pricci, F.6
-
17
-
-
28544446410
-
PPAR-gamma-agonists' renal effects
-
Izzedine H, Launay-Vacher V, Buhaescu I, Heurtier A, Baumelou A, Deray G. PPAR-gamma-agonists' renal effects. Minerva Urol Nefrol 2005; 57: 247-260.
-
(2005)
Minerva Urol Nefrol
, vol.57
, pp. 247-260
-
-
Izzedine, H.1
Launay-Vacher, V.2
Buhaescu, I.3
Heurtier, A.4
Baumelou, A.5
Deray, G.6
-
18
-
-
33744534329
-
Peroxisome proliferator-activated receptor gamma agonists in renal disease
-
Pedro I, Juan JD. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006; 154: 613-621.
-
(2006)
Eur J Endocrinol
, vol.154
, pp. 613-621
-
-
Pedro, I.1
Juan, J.D.2
-
19
-
-
0034033786
-
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
-
Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032.
-
(2000)
Diabetes
, vol.49
, pp. 1022-1032
-
-
Isshiki, K.1
Haneda, M.2
Koya, D.3
Maeda, S.4
Sugimoto, T.5
Kikkawa, R.6
-
20
-
-
0034810884
-
Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway
-
Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 2001; 38 (4 Suppl 1): s178-s181.
-
(2001)
Am J Kidney Dis
, vol.38
, Issue.4 SUPPL. 1
-
-
Haneda, M.1
Koya, D.2
Kikkawa, R.3
-
21
-
-
21344466513
-
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients
-
Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211.
-
(2005)
Diabetes
, vol.54
, pp. 2206-2211
-
-
Pistrosch, F.1
Herbrig, K.2
Kindel, B.3
Passauer, J.4
Fischer, S.5
Gross, P.6
-
22
-
-
0034758754
-
Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria
-
Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50: 1193-1196.
-
(2001)
Metabolism
, vol.50
, pp. 1193-1196
-
-
Nakamura, T.1
Ushiyama, C.2
Osada, S.3
Hara, M.4
Shimada, N.5
Koide, H.6
-
23
-
-
14744285718
-
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension
-
Sarafidis PA, Lasaridis AN, Nilsson PM, Hitoglou-Makedou AD, Pagkalos EM, Yovos JG, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005; 18: 227-234.
-
(2005)
Am J Hypertens
, vol.18
, pp. 227-234
-
-
Sarafidis, P.A.1
Lasaridis, A.N.2
Nilsson, P.M.3
Hitoglou-Makedou, A.D.4
Pagkalos, E.M.5
Yovos, J.G.6
|